NCT03623373 2026-03-30Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell LymphomaWashington University School of MedicinePhase 2 Completed13 enrolled 13 charts
NCT06191887 2026-02-13B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic MalignanciesMayo ClinicPhase 1 Recruiting27 enrolled